The DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index, and 1 are not checked yet.
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Open accessAbstract
Objective: We previously reported a characterisation of the hepatocellular carcinoma (HCC) immune contexture and described an immune-specific class. We now aim to further delineate the immunogenomic classification of HCC to incorporate features that explain responses/resistance to immunotherapy. Design: We performed RNA and whole-exome sequencing, T-cell receptor (TCR)-sequencing, multiplex immunofluorescence and immunohistochemistry in a novel cohort of 240 HCC patients and validated our results in other cohorts comprising 660 patients. Results: Our integrative analysis led to define: (1) the inflamed class of HCC (37%), which includes the previously reported immune subclass (22%) and a new immune-like subclass (15%) with high interferon signalling, cytolytic activity, expression of immune-effector cytokines and a more diverse T-cell repertoire. A 20-gene signature was able to capture ~90% of these tumours and is associated with response to immunotherapy. Proteins identified in liquid biopsies recapitulated the inflamed class with an area under the ROC curve (AUC) of 0.91; (2) The intermediate class, enriched in TP53 mutations (49% vs 29%, p=0.035), and chromosomal losses involving immune-related genes and; (3) the excluded class, enriched in CTNNB1 mutations (93% vs 27%, p<0.001) and PTK2 overexpression due to gene amplification and promoter hypomethylation. CTNNB1 mutations outside the excluded class led to weak activation of the Wnt-βcatenin pathway or occurred in HCCs dominated by high interferon signalling and type I antigen presenting genes. Conclusion: We have characterised the immunogenomic contexture of HCC and defined inflamed and non-inflamed tumours. Two distinct CTNNB1 patterns associated with a differential role in immune evasion are described. These features may help predict immune response in HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several gene signatures capturing the inflamed components of the TME have been associated with a favourable response to ICIs69,72,78–81, but none has been clinically validated thus far.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overall, patients with inflamed HCCs tend to have a favourable prognosis and are the most likely to have improved outcomes when receiving ICIs owing to the presence of responsive immune cells72,78.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Molecular classifications have identified classes of hepatocellular carcinoma associated with ICI responsiveness (inflamed class) and ICI resistance (excluded class).26”
From Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis (2024) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Inflamed tumours constitute ~30% of HCCs and exhibit extensive immune cell infiltration and immune activity, detected as increased expression of immune checkpoints (such as PD-1 or its ligand PD-L1), activation of IFN signalling and a low burden of large chromosomal alterations70,71,78.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationThe Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Villanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
Self-citationMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
D’Hulst, G., Soro-Arnaiz, I., Masschelein, E., Veys, K., Fitzgerald, G., Smeuninx, B., Kim, S., Deldicque, L., Blaauw, B., Carmeliet, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13889-6 · Cited by 2,310
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Self-citationCheng, A.-L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V., Merle, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.030 · Cited by 1,743
Khalifa, A. A. Z., Ichikawa, M., Dai, D., Kubo, S., Black, C. S., Peri, K., McAlear, T. S., Veyron, S., Yang, S. K., Vargas, J., et al. (2020) · eLife · doi:10.7554/elife.52760 · Cited by 1,676
Research works printed but not linked: 2
- Esteban-Fabró R , Willoughby CE , Piqué‐Gili M . Data from: cabozantinib enhances anti-PD1 efficacy and elicits a neutrophil-based immune response in murine models: implications for human HCC. gene expression Omnibus. Available: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE174570
- Hsu, 2021, Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma, Liver Cancer, 10, 346, 10.1159/000515305 · DOI
Cited by
Sorted by citations
Items 101–200 of 256
Cuproptosis- and m6A-Related lncRNAs for Prognosis of Hepatocellular Carcinoma
Zhu, Y., Tan, J. K., & Goon, J. A. (2023) · Biology · doi:10.3390/biology12081101 · Cited by 10
Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC
Piqué‐Gili, M., Andreu-Oller, C., Mesropian, A., Esteban-Fabró, R., Bárcena‐Varela, M., de Galarreta, M. R., Montironi, C., Martinez-Quetglas, I., Cappuyns, S., Peix, J., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101212 · Cited by 9
Self-citationKuwano, A., TANAKA, K., Takahira, J., Suzuki, H., Ohishi, Y., & Motomura, K. (2024) · In Vivo · doi:10.21873/invivo.13757 · Cited by 10
Chen, Y., Chen, D., Liang, Z., Yu, H., Sun, H., Hu, Y., Jiang, P., Zhang, M., Ye, L., & Li, H. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.120 · Cited by 9
Wang, Y., Guan, Y., Abbas, A. R., Sano, Y., Jain, S., Lu, S., Hamidi, H., Koeppen, H., Azuma, Y., Kayukawa, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102473 · Cited by 9
Self-citationLiu, Y. (2025) · Liver Cancer · doi:10.1159/000550163 · Cited by 12
Immunotherapy for Advanced Hepatocellular Carcinoma-a Large Tertiary Center Experience
Raj, R., Aykun, N., Wehrle, C. J., Maspero, M., Krishnamurthi, S., Estfan, B. N., Kamath, S. D., & Aucejo, F. (2023) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-023-05783-w · Cited by 9
Oshi, M., Chida, K., Roy, A. M., Mann, G. K., An, N., Yan, L., Endo, I., & Takabe, K. (2024) · Hepatology International · doi:10.1007/s12072-024-10678-2 · Cited by 9
Raghav, A., & Jeong, G. (2024) · Cells · doi:10.3390/cells13070638 · Cited by 9
Marsh‐Wakefield, F., Santhakumar, C., Ferguson, A. L., Ashhurst, T. M., Shin, J., Guan, F. H. X., Shields, N. J., Platt, B. J., Putri, G., Gupta, R., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000540 · Cited by 8
Comprehensive genomic profiling for advanced hepatocellular carcinoma in clinical practice
Terashima, T., Yamashita, T., Arai, K., Takata, N., Hayashi, T., Seki, A., Nakagawa, H., Nio, K., Iida, N., Yamada, S., et al. (2024) · Hepatology International · doi:10.1007/s12072-024-10741-y · Cited by 8
Advancements in immunotherapy for hepatocellular carcinoma
Ascari, S., Chen, R., Vivaldi, C., Stefanini, B., Sinno, A. D., Dalbeni, A., Federico, P., & Tovoli, F. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2461631 · Cited by 8
Kurebayashi, Y., Tsujikawa, H., Sugimoto, K., Yunaiyama, D., Araki, Y., Saito, K., Takahashi, H., Kakegawa, T., Wada, T., Tomita, Y., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13933 · Cited by 8
Meng, Q., Zhou, Q., Chen, X. X., & Chen, J. (2023) · Aging · doi:10.18632/aging.205173 · Cited by 8
Suzuki, T., Matsuura, K., Suzuki, Y., Okumura, F., Nagura, Y., Sobue, S., Matoya, S., Miyaki, T., Kimura, Y., Kusakabe, A., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6876 · Cited by 7
Zhang, S., Xu, L., Li, J.-Q., Du, M., Yin, Y., Zhong, B., Liang, H., Li, W.-C., Ni, C., & Zhu, X. (2024) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-024-03813-x · Cited by 8
Combination Therapies for Advanced Hepatocellular Carcinoma: Biomarkers and Unmet Needs
Cappuyns, S., & Llovet, J. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1213 · Cited by 8
Self-citationTokunaga, T., Tateyama, M., Kondo, Y., Miuma, S., Miyase, S., Tanaka, K., Narahara, S., Inada, H., Kurano, S., Yoshimaru, Y., et al. (2023) · Cancers · doi:10.3390/cancers15051568 · Cited by 8
Scheiner, B., Lombardi, P., D’Alessio, A., Kim, G., Tafavvoghi, M., Petrenko, O., Goldin, R. D., Fulgenzi, C. A. M., Torkpour, A., Balcar, L., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010975 · Cited by 7
Wan, S., Zhao, E., Freeman, D., Weissinger, D., Krantz, B. A., Werba, G., Khanna, L. G., Siolas, D., Oberstein, P. E., Chattopadhyay, P. K., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1067352 · Cited by 7
Minamiguchi, K., Irizato, M., Uchiyama, T., Taiji, R., Nishiofuku, H., Marugami, N., & Tanaka, T. (2023) · European Radiology · doi:10.1007/s00330-023-09950-0 · Cited by 7
High CD49a+ NK cell infiltrate is associated with poor clinical outcomes in Hepatocellular Carcinoma
Zecca, A., Barili, V., Boni, C., Fisicaro, P., Vecchi, A. L., Rossi, M., Reverberi, V., Montali, A., Pedrazzi, G., Ferrari, C. I., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22680 · Cited by 7
Radio-immunomics in hepatocellular carcinoma: Unraveling the tumor immune microenvironment
Liu, Q., Zhu, W., Song, F., Lou, T., He, L., Zhou, W., & Feng, Z. (2024) · Meta-Radiology · doi:10.1016/j.metrad.2024.100098 · Cited by 7
Hernáez, R., & Avila, M. A. (2022) · Gut · doi:10.1136/gutjnl-2022-327132 · Cited by 7
Müller, L., Gairing, S. J., Kloeckner, R., Foerster, F., Schleicher, E. M., Weinmann, A., Mittler, J., Stoehr, F., Halfmann, M. C., Düber, C., et al. (2022) · Cancer Imaging · doi:10.1186/s40644-022-00487-x · Cited by 7
A prognostic cuproptosis-related lncRNA predictive signature for bladder cancer patients
Jiang, S., Zhang, J., Fan, Q. W., Li, Z., Dou, R., Lin, Z., Chen, Z., Xu, Y. M., Huang, Z., Lan, J., et al. (2023) · Human Cell · doi:10.1007/s13577-023-00863-0 · Cited by 7
Recent developments in molecular targeted therapies for hepatocellular carcinoma in the genomic era
Testa, U. (2024) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2024.2392278 · Cited by 7
Seraphin, T. P., Mesropian, A., Žigutytė, L., Brooks, J. A., Mauro, E., Gris‐Oliver, A., Pinyol, R., Montironi, C., Balaseviciute, U., Piqué‐Gili, M., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101592 · Cited by 6
Self-citationChan, L. L., Chan, K. O. K., & Chan, S. L. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70354 · Cited by 7
From Theory to Practice: Which Biomarkers Are Ready for Predicting Response in Advanced HCC ?
Decraecker, M., Blanc, J., Amintas, S., & Manaud, G. (2026) · Liver International · doi:10.1111/liv.70684 · Cited by 7
Tabrizian, P., Zeitlhoefler, M., Hassan, A. T., & Marino, R. (2023) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001133 · Cited by 6
Balsano, R., Pino, M., Bocchero, E., Valenzi, E., Pressiani, T., Bozzarelli, S., & Rimassa, L. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2557625 · Cited by 5
Boilève, J., Guimas, V., David, A., Bailly, C., & Touchefeu, Y. (2024) · Current Oncology · doi:10.3390/curroncol31060242 · Cited by 6
Cowzer, D., Chou, J. F., Walch, H. S., Keane, F., Khalil, D. N., Shia, J., Do, R. K. G., Yarmohammadi, H., Erinjeri, J. P., Dika, I. E., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae110 · Cited by 5
Fang, Z., Liu, C.-X., Cheng, Y., Ji, Y., & Liu, C. (2025) · Life Science · doi:10.1016/j.lfs.2025.123377 · Cited by 5
Bouguerra, R., Hajji, S. E., Wassmer, C., Bakaric, A., Slits, F., Moeckli, B., Rubbia‐Brandt, L., Lacotte, S., & Toso, C. (2025) · Hepatology · doi:10.1097/hep.0000000000001575 · Cited by 7
Barsch, M., Salié, H., Mesesan, A., & Bengsch, B. (2023) · Liver Cancer International · doi:10.1002/lci2.72 · Cited by 5
Pourbagheri‐Sigaroodi, A., Fallah, F., Bashash, D., & Karimi, A. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3913 · Cited by 6
Battista, D. D., Yakymi, R., Scheibe, E., Sato, S., Gerstein, H., Markowitz, T. E., Lack, J., Mereu, R., Manieli, C., Zamboni, F., et al. (2024) · Cancers · doi:10.3390/cancers16071370 · Cited by 5
Nishida, N. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0739 · Cited by 5
You, W., Hu, C., Zhao, M., Zhang, Y., Lu, J., Huang, Y., Li, L., & Chen, Y. (2024) · Gut · doi:10.1136/gutjnl-2024-333375 · Cited by 5
Shi, Y., Feng, Y., Qiu, P., Zhao, K., Li, X., Deng, Z., & Wang, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1298290 · Cited by 5
Choi, H., Na, K. J., Jung, Y., Lim, M., Lee, D., Lee, J. E., Im, H., Lee, D., Koh, J., & Kim, Y. T. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.16.594592 · Cited by 5
Li, S., Wang, X., Xiao, J., & Yi, J. (2025) · European journal of medical research · doi:10.1186/s40001-025-02411-y · Cited by 4
Han, Y., Wu, H., Zhang, X., Lv, W., Xiong, Y., Tian, X., Xiao, Y., & Cui, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-03144-4 · Cited by 5
Kanzaki, H., Ishino, T., Ogasawara, S., Tsuchiya, T., Fujiya, M., Sawada, M., Izai, R., Akatsuka, T., Miwa, C., Yonemoto, T., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101614 · Cited by 4
Ma, F., Li-Li, L.-L., Xu, Z., Xie, Y. L., Ma, Y., & Li, P. (2025) · European journal of medical research · doi:10.1186/s40001-025-03403-8 · Cited by 4
Circular RNA in hepatocellular carcinoma: emerging therapeutic strategies
Jazbec, G., & Režen, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1722576 · Cited by 4
Pan, Q., Wang, X., Li, B., Cai, Z., Chen, S., Hu, J., Yuan, X., Yang, J., Guo, A., & Zhang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1766301 · Cited by 4
Molecular insights into early malignant transition of hepatocellular carcinoma
ZHANG, Z., li, H., Chen, L., Lu, T., Shentu, X., Liu, Y., Tang, Z., Ji, S., Qiu, Z., Zou, Y., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.03.005 · Cited by 4
Self-citationHuman GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts
Weinfurtner, K. M., Tischfield, D. J., McClung, G., Brain, J. A., Gordan, J. D., Jiao, J., Furth, E. E., Li, W., Supan, E. T., Nadolski, G., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101264 · Cited by 4
Ozaki, K., & Goshima, S. (2025) · Abdominal Radiology · doi:10.1007/s00261-025-05169-3 · Cited by 4
Molecular profiling reveals potential targets in cholangiocarcinoma
Liu, D., Shi, Y., Chen, H., Nisar, M. A., Jabara, N., Langwinski, N., Mattson, S., Nagaoka, K., Bai, X., Lu, S., et al. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i25.4053 · Cited by 4
Rakké, Y. S., Buschow, S. I., IJzermans, J. N. M., & Sprengers, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1357333 · Cited by 4
A signature-based classification of lung adenocarcinoma that stratifies tumor immunity
Zhang, X., Jiang, D., Li, S., Zhang, X., Zheng, W., & Cheng, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1023833 · Cited by 4
Li, B., Wen, J., Xu, Z., Yan, P., Han, B., & Yu, D. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0628 · Cited by 4
Cheng, C. C. Y., Cheung, M. F., Lee, A. Y., Wu, Q., Chow, S. H.-C., Ang, J. Y. J., Riquelme Medina, I., Lo, G., Wu, H., Yang, W., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-09154-w · Cited by 3
Kuwano, A., Yada, M., Tanaka, K., Takahira, J., Suzuki, H., Ohishi, Y., & Motomura, K. (2025) · Hepatology Research · doi:10.1111/hepr.14157 · Cited by 3
Wang, T.-C., Huang, W., Li, S.-X., Li, J., Zhou, P., Wang, L., Wei, N., Cai, W., Hu, J., & Xiao, Y. (2025) · Academic Radiology · doi:10.1016/j.acra.2025.04.016 · Cited by 4
Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma
Foerster, F., Wiesmann, L., Bark, P., & Galle, P. R. (2025) · Hepatology · doi:10.1097/hep.0000000000001554 · Cited by 3
Pan, Y., Zeng, C., He, Y. L., Chang, R., Wu, J., Yuan, C., Li, H., Su, C., Han, M., Li, P., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68156-8 · Cited by 3
METTL5 promotes tumor progression and ferroptosis resistance via MGST1 in HCC
Ji, T., Miao, X., Fang, Y., Nie, J., Zhu, Q., Zhu, P., Liao, W., & Yang, D. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05475-w · Cited by 3
Li, Y., Tan, X., Fang, S., & So, C. (2026) · Clinical Oncology · doi:10.1016/j.clon.2026.104075 · Cited by 4
Li, J.-R., Pan, L.-X., Su, J., Tian, W., Lin, L.-P., Huang, Z.-H., Luo, C., Li, Z.-Z., Ma, L., Guo, P., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000925 · Cited by 3
Adán-Villaescusa, E., Castelló-Uribe, B., Uriarte, I., Santamaría, E., Barbero, R., Belzunce, M., López-Pascual, A., Latasa, M. U., Elurbide, J., Valbuena-Goiricelaya, E., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102717 · Cited by 3
Self-citationGorgulho, J., Masood, R., Buescher, G., Giehren, F., Salié, H., David, D., Pagani, F., Kocheise, L., Schmidt, C., Waldmann, M., et al. (2026) · Gut · doi:10.1136/gutjnl-2025-337617 · Cited by 4
Gonvers, S., Martins-Filho, S. N., Hirayama, A. L. D. S., Caldéraro, J., Phillips, R., Uldry, É., Demartines, N., Melloul, E., Park, Y. N., Paradis, V., et al. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s447848 · Cited by 3
Self-citationHeterogeneity in Liver Cancer Immune Microenvironment: Emerging Single-Cell and Spatial Perspectives
Li, C. C., Liu, M., Lee, H.-P., Wu, W., & Ma, L. (2024) · Seminars in Liver Disease · doi:10.1055/s-0044-1787152 · Cited by 3
Carcinome hépatocellulaire : classifications histologiques et moléculaires
Bèaufrere, A., & Paradis, V. (2024) · Annales de Pathologie · doi:10.1016/j.annpat.2024.10.004 · Cited by 3
Su, Y., Liang, Y., Zhong, D., Yan, H., Yang, Q., Shang, J., Chen, Y., & Huang, X. (2025) · BMC Cancer · doi:10.1186/s12885-025-13867-w · Cited by 3
Wei, Y., Su, H., Lv, Z., Liao, X., Zeng, Z., Jia, Y.-X., Huang, H.-S., Shen, X.-Q., Zhu, G., Han, C., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1165538 · Cited by 3
Breitenecker, K., Heiden, D., Demmer, T., Weber, G., Primorac, A.-M., Hedrich, V., Ortmayr, G., Gruenberger, T., Starlinger, P. P., Herndler‐Brandstetter, D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084202 · Cited by 3
Akiba, J., Ogasawara, S., & Yano, H. (2024) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20445 · Cited by 3
Yang, S.-Y., Li, S., Li, T., Ma, D.-J., Yu, J., Liu, Y., Yu, Y., Li, X., Zang, J., Yuan, Z., et al. (2025) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c06867 · Cited by 2
Lee, K., Kim, S., Zhao, J., & Neo, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1631258 · Cited by 2
Integrating gut microbiome and host transcriptomics for the personalized management of IBD
Barry, D., Thachuk, C., & Trink, J. (2025) · Epigenomics · doi:10.1080/17501911.2025.2591594 · Cited by 3
DePietro, D. M., Kiefer, R. M., Weinfurtner, K. M., & Hung, M. L. (2026) · Digestive Disease Interventions · doi:10.1055/a-2779-5302 · Cited by 2
An immunocompetent murine model of virus-elicited liver fibrosis and hepatocellular carcinoma
Batista, M. N., Bordignon, J., Mosimann, A. L. P., Bobrowski, T., Chen, H.-A., Tobin-Xet, G., Barrall, E. A., Prokhnevska, N., Vaidya, A. B., Lewy, T., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.02.020 · Cited by 2
Hazari, M. W. A. D., Nandi, S., & Das, C. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153656 · Cited by 3
Pan, L., Hirsch, T., Fang, J., Seretny, A., Imbeaud, S., Jin, S., Gege, O. O., Rebouissou, S., Sidali, S., Ammiche, N., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73212-y · Cited by 1
Self-citationPark, C., Wong, T. L., & K, S. (2026) · Carcinogenesis · doi:10.1093/carcin/bgag040 · Cited by 3
Li, Y., Ding, Y., Wang, J., Wu, X., Zhang, D., Zhou, H., Zhang, P., & Shao, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1466069 · Cited by 2
Yu, K., Zhong, Q., Zhang, J., & Huang, C. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096370558250514063841 · Cited by 2
Aoki, T., Nishida, N., & Kudo, M. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0435 · Cited by 2
Ding, T., Li, X., Mo, J., Alexander, G., & Li, J. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011716 · Cited by 1
Bárcena‐Varela, M., & Berraondo, P. (2024) · Gut · doi:10.1136/gutjnl-2023-331647 · Cited by 1
Kuwano, A., Yada, M., Koga, Y., Tanaka, K., Ohishi, Y., Masumoto, A., & Motomura, K. (2024) · Oncology Letters · doi:10.3892/ol.2024.14442 · Cited by 1
Fernandes, W. M., Harris, N., Zamalloa, A., Adofina, L., Srinivasan, P., Menon, K. V., Heaton, N. D., Miquel, R., Zen, Y., Kelly, G. P., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168924 · Cited by 1
Cheng, J., Zheng, Q.-Y., Huang, Y.-L., Chen, Y., & Du, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189406 · Cited by 1
Zhang, B.-X. B., Lin, H.-Y., Tran, H. Y., Wu, C.-C., Chen, K.-Y., Hsu, T.-I., & Shen, C.-J. (2026) · Immunobiology · doi:10.1016/j.imbio.2026.153163 · Cited by 1
Zorigtbaatar, A., Moral, K., Sapisochín, G., Kabaçam, G., Selzner, N., Tabrizian, P., & Marino, R. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000004958 · Cited by 2
Liu, H. Q., He, Q., Wang, D., Liu, J. T., Qu, Y., Zhang, D., Sun, P., Li, H., Peng, S., Li, R., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114991 · Cited by 1
Advances in oncolytic viruses immunotherapy of hepatocellular carcinoma
You, S., Wang, M., Zhang, T., Wang, Q., Zhang, M., Wang, H., Hua, X., Su, Y., Li, Y., Qu, P., et al. (2026) · Discover Oncology · doi:10.1007/s12672-026-05364-8 · Cited by 1
Self-citationZhang, L., Tang, N., Yang, C. G., Geng, H., Hang, H., Qin, W., & Wang, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01262-x · Cited by 1
WEE Family Kinase Inhibitors Combined with Sorafenib Can Selectively Inhibit HCC Cell Proliferation
Chen, A., Yin, K., Liu, Y., Hu, L., Cui, Q., Wan, X., & Yang, W. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096298370240520093003 · Cited by 1
Wang, F., Deng, L., Li, Z., Cao, Q., Jiang, R., Xu, C., & Yang, J. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251329699 · Cited by 1
Krishna, A., Meynert, A. M., Kelder, M. J. E., Ewing, A., Sheraz, S., Ferrer‐Vaquer, A., Grimes, G. R., Becher, H., Silk, R., Semple, C. A. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.09.566307 · Cited by 1
Правовой плюрализм и юридическая деятельность
Викторович, Б. С. (2012) · Вестник Омского университета. Серия «Право»
Advanced HCC precision modeling reveals divergent responses to combinatorial immunotherapyPreprint
Liu, J., Cheng, L., El‐Mekkoussi, H., Lee, M., Jaffe, D. R., Gavin-Darby, K., Morgan, A. R., Manduchi, E., Schug, J., & Kaestner, K. H. (2022) · Research Square · doi:10.21203/rs.3.rs-1919053/v1
Esteban-Fabró, R., Willoughby, C. E., Piqué‐Gili, M., Montironi, C., Abril‐Fornaguera, J., Peix, J., Torrens, L., Mesropian, A., Balaseviciute, U., Miró‐Mur, F., et al. (2023) · doi:10.1158/1078-0432.22482765.v1
Self-citation
Metadata
- Authors
- Montironi, C., Castet, F., Haber, P. K., Pinyol, R., Torres-Martin, M., Torrens, L., Mesropian, A., Wang, H., Puigvehi, M., Maeda, M., Leow, W. Q., Harrod, E., Taik, P., Chinburen, J., Taivanbaatar, E., Chinbold, E., Solé Arqués, M., Donovan, M., Thung, S., Neely, J., Mazzaferro, V., Anderson, J., Roayaie, S., Schwartz, M., Villanueva, A., Friedman, S. L., Uzilov, A., Sia, D., & Llovet, J. M.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- Tisch Cancer Institute (US)
- Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
- Sema4 (United States) (US)
- Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Singapore General Hospital (SG)
- Royal Surrey County Hospital (GB)
- Hepato-Pancreatico-Biliary Surgery Department, National Cancer Center, Ulaanbaatar, Mongolia
- Bristol-Myers Squibb (United States) (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- White Plains Hospital (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Llovet, Josep M
- ORCID
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2022-02-23
- Volume
- 72
- Issue
- 1
- Pages
- 129-140
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- PMC
- PMC9395551
- OpenAlex
- W4213062169
- Cited by
- 253
- References
- 49
- Citations by year
- 2026: 48 · 2025: 52 · 2024: 66 · 2023: 67 · 2022: 19
- FWCI
- 21.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Gut (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Funders
- Dr. Franklin M. Klion Young Scientist Research Award (N/A)
- Generalitat de Catalunya (PERIS (SLT017/20/000206))
- National Cancer Institute (P30-CA196521)
- PhD Scientist Innovative Research Award (N/A)
- Instituto de Salud Carlos III (Rio Hortega grant (CM19/00039))
- Samuel Waxman Cancer Research Foundation (N/A)
- Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i de Balears (N/A)
- Cancer Research UK (HUNTER, Ref. C9380/A26813)
- Associazione Italiana per la Ricerca sul Cancro (HUNTER, Ref. C9380/A26813)
- U.S. Department of Defense (CA150272P3)
- Tisch Cancer Institute (N/A)
- Horizon 2020 Framework Programme (HEPCAR, Ref. 667273-2)
- Deutsche Forschungsgemeinschaft (DFG: HA 8754/1-1)
- Fundación Científica Asociación Española Contra el Cáncer (CLJUN20007CAST, HUNTER, Ref. C9380/A26813)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (SAF2016-76390)
- Agència de Gestió d’Ajuts Universitaris i de Recerca (SGR-1358)
- Bristol-Myers Squibb (N/A)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK128289, R01-128289, R01-56621)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- hepatocellular carcinoma, immune evasion, immunotherapy response prediction, interferon signaling, T cell receptor repertoire, TP53 mutation, CTNNB1 mutation, Wnt/β-catenin signaling, promoter hypomethylation, liquid biopsy, gene expression signatures, immune-related genes
- MeSH terms
- Carcinoma, Hepatocellular, Humans, Interferons, Liver Neoplasms, Mutation, DNA Methylation, Wnt Signaling Pathway
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
